Integrated Motor-Cognitive Training in Parkinson's Disease: A Feasibility Study (P_Feasibility)
Parkinson's disease is a progressive neurodegenerative condition characterized by both motor symptoms (such as bradykinesia, rigidity, tremor, and postural instability) and non-motor symptoms, including cognitive impairments (affecting working memory, executive functions, and attention). Combined interventions that target both domains simultaneously or consecutively have shown potential to produce superior benefits compared to isolated motor or cognitive training.
The purpose of this study is to evaluate the feasibility, adherence, and preliminary clinical results of efficacy of an integrated and combined motor-cognitive rehabilitation training in patients diagnosed with Parkinson's disease.
This feasibility study will enroll 12 participants with Parkinson's disease. All participants will undergo a comprehensive 10-session integrated rehabilitation program combining digital cognitive individual stimulation and group functional motor training. The primary focus is to assess acceptability, safety, and adherence to this combined approach, while secondary outcomes will observe changes in relevant cognitive and motor clinical variables.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Sofia Straudi, MD, PhD
- Telefonní číslo: +390532238720
- E-mail: sofia.straudi@unife.it
Studijní místa
-
-
FE
-
Ferrara, FE, Itálie, 44124
- Nábor
- Ferrara University Hospital
-
Kontakt:
- Sofia Straudi, MD, PhD
- Telefonní číslo: 0532238720
- E-mail: sofia.straudi@unife.it
-
Dílčí vyšetřovatel:
- Gaia Palma, PhD student, Psychologist
-
Dílčí vyšetřovatel:
- Andrea Baroni, Physiotherapist, PhD
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Diagnosis of Parkinson's disease
- Presence of motor symptoms attributable to Parkinson's disease
- Availability to participate in both treatments (cognitive and motor)
- Severity of symptoms compatible with participation in group physical therapy
- Absence of other medical conditions that could interfere with treatment delivery
- Montreal Cognitive Assessment (MoCA) score >= 18
- Consent to participate in group-based motor training
- Absence of falls in the 3 months prior to baseline evaluation
Exclusion Criteria:
- Concomitant major neurological or psychiatric disorders
- Severe cardio-pulmonary, renal, or hepatic diseases
- Changes in baseline pharmacological therapy within 3 months prior to enrollment
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Combined Motor-Cognitive Training Group
Participants will receive a 10-session integrated rehabilitation program combining individual digital cognitive stimulation and group functional motor training |
Participants complete a 10-session motor-cognitive training program (3 times per week). Interventions occur on the same day in groups of 3, supervised by a neuropsychologist and physiotherapist.
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Feasibility Outcomes: Eligibility Rate
Časové okno: Baseline
|
Calculated as the ratio of eligible patients to the total number of screened patients. |
Baseline
|
|
Feasibility Outcomes: Recruitment Rate
Časové okno: Baseline
|
Calculated as the ratio of recruited patients to total eligible patients. |
Baseline
|
|
Feasibility Outcomes: Monthly Recruitment Rate
Časové okno: Baseline
|
Defined as the average number of participants enrolled per month. |
Baseline
|
|
Feasibility Outcomes: Drop-out Rate
Časové okno: score changes after intervention (4 weeks, T1)
|
The percentage of participants who withdraw from the study. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Adherence Rate
Časové okno: score changes after intervention (4 weeks, T1)
|
The percentage of scheduled training sessions attended |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Longitudinal Retention Rate
Časové okno: Post-intervention follow-up assessment (3 months after intervention completion)
|
The percentage of enrolled participants who complete all follow-up assessments |
Post-intervention follow-up assessment (3 months after intervention completion)
|
|
Feasibility Outcomes: Self-Reported Acceptability
Časové okno: score changes after intervention (4 weeks, T1)
|
Participants will complete a questionnaire at the end of the intervention to evaluate their subjective experience, perceived benefits, and difficulties of the treatment. Items are rated on a 5-point Likert scale ranging from 1 ("low") to 5 ("extremely high"), with higher scores indicating a more positive evaluation or greater perceived benefit/difficulty. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Adverse Events
Časové okno: score changes after intervention (4 weeks, T1)
|
The incidence and severity of any adverse events (e.g., falls or excessive fatigue) recorded during the study. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Motor Exercise Intensity
Časové okno: Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
The Borg Rating of Perceived Exertion (RPE) will be used to monitor and quantify physical and cognitive effort. Total score ranges from 6 to 20. Higher scores indicate greater perceived exertion |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
|
Feasibility Outcomes: Motor Exercise Exertion
Časové okno: Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
The Borg Intensity Scale-Exerciser (BIS-E) will be used to quantify exertion. Total score ranges from 0 to 30, higher scores indicate greater perceived balance effort, difficulty, and postural instability during circuit stations. |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
|
Feasibility Outcomes: Digital Cognitive Progression Index (NeuronUP Activity Score)
Časové okno: Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
Digital Cognitive Progression Index (NeuronUP Activity Score) will be used to quantifies session-by-session cognitive performance and adaptive difficulty progression across the 10 training sessions. The score is calculated using NeuronUP's standardized algorithm based on accuracy, total completed phases, and maximum difficulty reached, yielding a score from 0 to 100. Higher scores reflect greater task proficiency and successful progression to higher difficulty levels. This metric serves as an exploratory/feasibility measure of intra-intervention cognitive learning. |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Motor Outcomes: Change in dynamic balance, mobility, and gait
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Timed Up and Go Test (TUG Single Task) will be used to assess the change in dynamic balance, mobility, and gait. Evaluated as time (in seconds). Lower time indicates better functional mobility. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Gait speed
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
10-Meter Walk Test (10MWT) will be used to assess change in gait speed over a 10-meter distance. Evaluated as speed in meters per second (m/s). Higher values indicate faster walking speed and improved gait dynamics. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Distance Walked
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The 6-Minute Walk Test (6MWT) will be used to assess change in total distance walked (in meters) within 6 minutes. Evaluated as total distance walked (in meters) within 6 minutes. Higher distance indicates superior physical endurance. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Dynamic Balance
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
Mini-BESTest Total Score will be used to assess change dynamic balance abilities across four subscales (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait).Total score ranges from 0 to 28, with higher scores indicating superior dynamic balance and lower fall risk. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Finger motor speed
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Finger Tapping Test Performance will be used to assess motor speed. Measures include total number of taps (right and left hand). Higher tap counts indicate better motor control. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Global cognitive function
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Montreal Cognitive Assessment (MoCA) total score will be used to assess global cognitive function. The scale ranges from 0 to 30, with higher scores indicating better global cognitive function (a score of 26 or above is generally considered normal). |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Visual search and processing speed
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Trail Making Test Part A (TMT-A) will be used to assess visual search abilities and processing speed. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in executive function, cognitive flexibility, and set-shifting.
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Trail Making Test Part B (TMT-B) Time will be used to assess executive function, cognitive flexibility, and set-shifting. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Information processing speed and attention
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Symbol Digit Modalities Test (SDMT) will be used to assess information processing speed and attention. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Decision-making processing speed and cognitive-motor control
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Choice Reaction Time (CRT) Task will be used to assess decision-making processing speed and cognitive-motor control. Evaluated via number of correct responses, mean reaction time (in milliseconds) for correct responses, and mean reaction time for error responses. Lower reaction times and higher correct rates indicate better performance. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in perceptive-motor speed
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Simple Reaction Time (SRT) will be used to assess reaction time speed. Evaluated as mean reaction time (in milliseconds) for correct responses and number of correct responses. Lower reaction times indicate faster processing speed; Higher correct responses indicate better accuracy. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Change in Quality of Life
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The EQ-5D Quality of Life Questionnaire will be used to assess health-related quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Higher scores indicate superior quality of life. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Change in Fatigue
Časové okno: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Parkinson Fatigue Scale (PFS-16) will be used to assess the impact of fatigue specific to Parkinson's disease. Total mean score ranges from 1 to 5. Higher scores indicate greater perceived fatigue. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 710/2025/Oss/AOUFe
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .